Jump to any asset
849 assets, updated daily
Gilead Sciences vs Bristol-Myers Squibb Company
VS
Comparative Analysis
Bristol Myers Squibb (BMY) emerges as the preferred investment over Gilead Sciences (GILD) due to its superior profitability and more attractive valuation, despite GILD's stronger recent revenue growth. BMY demonstrates significantly higher net profit margins and return on equity, indicating more efficient operations and better shareholder value creation. While GILD has shown stronger recent revenue expansion, BMY's current financial health and valuation metrics present a more compelling case for investors seeking stability and efficiency in the pharmaceutical sector. BMY's current price of $62.86 is trading below its 50-day ($64.35) and 200-day ($59.14) moving averages, suggesting some short-term weakness but also potential for mean reversion. GILD, trading at $150.93, is above its 50-day ($141.48) and 200-day ($135.99) averages, indicating a more established uptrend. However, BMY's recent earnings beats and higher analyst target median relative to its current price offer a more immediate upside potential. The dividend yield also favors BMY, providing a higher income stream for investors.
Key Differentiator
The decisive factor favoring Bristol Myers Squibb (BMY) is its demonstrably superior profitability. BMY's net profit margin and return on equity are substantially higher than GILD's, indicating a more efficient and financially sound operation. This profitability advantage, coupled with a more attractive valuation, presents a stronger case for investment despite GILD's more positive technical trend.
Joint Outlook
Bristol Myers Squibb (BMY) is expected to see potential upside driven by its oversold technicals and strong profitability, assuming it can maintain its earnings momentum and navigate upcoming patent cliffs. A successful pipeline execution could see BMY re-test its 50-day moving average around $64.35 and potentially move higher. Gilead Sciences (GILD) is in a more established uptrend, supported by positive revenue growth and analyst optimism. However, its negative profit margins and lower dividend yield present headwinds. If GILD can improve its profitability and continue to grow revenue, it could challenge its 52-week high of $157.29. The next 6-12 months will be critical for both companies to demonstrate sustained earnings power and pipeline success.
Price Analysis Comparison
Valuation Metrics
| Metric | GILD | BMY |
|---|---|---|
| P/E Ratio | 17.87 | 13.47 |
| Market Cap | 187.15B | 128.41B |
| Price/Sales | 6.16 | 2.54 |
| Price/Book | 15.88 | 5.60 |
| EV/EBITDA | 14.31 | 8.39 |
| Dividend Yield | 2.15% | 3.99% |
Bristol Myers Squibb (BMY) presents a more attractive valuation with a Price-to-Earnings ratio of 13.47 compared to Gilead Sciences (GILD) at 17.87. This suggests BMY is cheaper on an earnings basis, offering more value for the price paid. Also, BMY's current price of $62.86 is closer to its 52-week low of $42.52 than GILD's price of $150.93 is to its 52-week low of $108.46. This positioning indicates that BMY may have more room for appreciation and is trading at a more significant discount relative to its recent trading range. GILD, while in a more established uptrend, is trading closer to its 52-week high, suggesting less immediate upside potential from a valuation perspective.
Profitability & Efficiency
| Metric | GILD | BMY |
|---|---|---|
| Rev. Growth (Qtly) | 10.20% | 5.70% |
| Profit Margin | -10.64% | 18.87% |
| Return on Equity | -20.68% | 46.60% |
| Return on Assets | 14.09% | 10.72% |
| Debt/Equity | 223.47 | 201.86 |
Bristol Myers Squibb (BMY) significantly outperforms Gilead Sciences (GILD) in profitability metrics. BMY boasts a net profit margin of 18.87% and a return on equity of 46.6%, demonstrating superior operational efficiency and ability to generate profits from shareholder investments. In contrast, GILD exhibits a negative net profit margin of -10.64% and a negative return on equity of -20.68%. While GILD's return on assets is a positive 14.09%, BMY's return on assets at 10.72% is lower, but its overall profitability picture is far stronger due to its positive net margin and ROE. These figures highlight BMY's stronger financial health and effective management of its resources.
Earnings Reality Check
GILD
Last 5 Qs: GILD beat estimates 5x out of 5. Fell 3x after beats. (Sell the news?)
BMY
Last 4 Qs: BMY beat estimates 4x out of 4. Rose 3x after beats.
Technical Indicators
| Indicator | GILD | BMY |
|---|---|---|
| RSI (14) | 49.84 | 27.35 |
| 50-Day MA | $141.48 | $64.35 |
| 200-Day MA | $135.99 | $59.14 |
Bristol Myers Squibb (BMY) is currently showing signs of weakness, with its RSI at 27.35 and CCI at -65.19, indicating oversold conditions and potential for a bounce. The stock is trading below its 20-day EMA ($63.65), 50-day SMA ($64.35), and 200-day SMA ($59.14), suggesting a bearish short-to-medium term trend. Gilead Sciences (GILD) presents a more constructive technical picture, with an RSI of 49.84 and CCI of 46.70, indicating neutral momentum. GILD is trading above its 20-day EMA ($148.17), 50-day SMA ($141.48), and 200-day SMA ($135.99), confirming an uptrend. However, BMY's oversold technicals suggest a higher probability of short-term price recovery compared to GILD's more stable but less immediately opportunistic trend.
AI Analyst Sentiment
Technical rating: based on current price action versus moving averages and momentum. This measures short-term chart trend, not analyst opinion or company fundamentals.
GILD
Technical Score: 72/100
BMY
Technical Score: 59/100
Gilead Sciences (GILD) garners a more bullish analyst sentiment, with a median target price of $162, representing a potential upside of approximately 7.3% from its current price of $150.93. The analyst ratings are predominantly 'Strong Buy' and 'Buy'. Bristol Myers Squibb (BMY) also receives favorable analyst ratings, with a median target price of $68, suggesting an upside of approximately 8.2% from its current price of $62.86. While BMY has a higher proportion of 'Hold' ratings compared to GILD, the overall analyst consensus leans positive for both, with BMY offering a slightly better implied upside based on its current price relative to its median target.
Note: While GILD shows stronger short-term technical momentum (Buy 72/100), the AI comparative analysis favors BMY (Hold 59/100) based on its overall trend structure, fundamentals, and risk-adjusted outlook.
Risk Stratification
| Metric | GILD | BMY |
|---|---|---|
| Beta (Volatility) | 0.35 | 0.23 |
| Sharpe Ratio | 1.20 | 0.61 |
Bristol Myers Squibb (BMY) faces risks related to patent expirations for key drugs and increasing competition within the pharmaceutical market. Its recent negative EPS in one quarter, though a beat, highlights potential earnings volatility and the need for successful pipeline development to sustain growth. Gilead Sciences (GILD) carries risks associated with its significant debt load and the ongoing challenges in its antiviral and oncology segments. While GILD has shown revenue growth, its negative profit margins and return on equity indicate underlying operational inefficiencies or high cost structures that could hinder long-term profitability. Both companies are subject to regulatory changes and clinical trial outcomes, which can significantly impact their future prospects.
Comparative ProTips
- Consider BMY for its current profitability advantage and attractive valuation, with potential for a technical rebound.
- GILD remains in a technical uptrend, but its negative profit margins present a significant risk factor.
- Investors prioritizing income should favor BMY due to its higher dividend yield.
Monte Carlo Projection (10yr)
Actionable Trade Plans
Compare entry, exit, and risk management levels for both assets
Select Your Trade Bias
Risk Tolerance
Conservative
3%
Aggressive
Portfolio Value
$
✎
Position Size: $200 - $300 per asset
GILD
Current: $150.93
ENTRY ZONES
Conservative
$143.38
Aggressive
$150.93
RISK MANAGEMENT
STOP LOSS
$139.08
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$150.55
+10%
$157.72
+15%
$164.89
BMY
Current: $62.86
ENTRY ZONES
Conservative
$59.72
Aggressive
$62.86
RISK MANAGEMENT
STOP LOSS
$57.93
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$62.70
+10%
$65.69
+15%
$68.67
Calculate Your Trade
Disclaimer
This comparison involves assets with varying risk profiles. The content is for educational purposes only. Identifying the stronger asset is based on relative strength (RS) and technical convergence. Past correlation does not guarantee future lockstep movement. Trading involves risk of loss. Note: The AI favored BMY based on profitability metrics. This is valid for the specified timeframe only. While GILD currently shows the stronger short-term technical score (72 vs 59), the AI favors BMY on the factors above rather than today's technical setup.
Frequently Asked Questions
Which is a better buy, GILD or BMY?+
BMY is a better buy due to its superior profitability (18.87% net margin vs GILD's -10.64%) and more attractive valuation (P/E of 13.47 vs GILD's 17.87). BMY also offers a higher dividend yield of 3.99% compared to GILD's 2.15%.
What are the key risks for GILD vs BMY?+
GILD faces risks from patent expirations and challenges in its core segments, alongside negative profit margins. BMY's risks include patent cliffs and competitive pressures, with recent earnings volatility also a concern.
How do GILD and BMY compare on valuation?+
BMY is cheaper with a P/E of 13.47 versus GILD's 17.87. BMY also trades closer to its 52-week low, suggesting more potential upside compared to GILD.
Which stock offers a better dividend yield?+
BMY offers a higher dividend yield of approximately 3.99%, compared to GILD's yield of approximately 2.15%.
How do their recent earnings compare?+
BMY had a strong earnings beat in its latest quarter (+27.5%), while GILD also beat estimates (+6.9%) but reported negative EPS. BMY's earnings history shows more consistent positive surprises.
What are the technical outlooks for GILD and BMY?+
GILD is in a confirmed uptrend, trading above key moving averages. BMY is showing oversold technicals (RSI 27.35) and trading below its averages, suggesting potential for a short-term rebound.
Which company has better profitability metrics?+
BMY demonstrates significantly better profitability with a net profit margin of 18.87% and a return on equity of 46.6%, whereas GILD has negative margins and ROE.